Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have
stage IV colorectal cancer. Imatinib mesylate may interfere with the growth of tumor cells by
blocking certain enzymes necessary for cancer cell growth